Work

A genomic analysis of Philadelphia chromosome-negative AML arising in patients with CML

Year: 2016

Type: article

Abstract: Chronic myelogenous leukemia (CML) is characterized by the Philadelphia chromosome, an acquired clonal abnormality resulting from translocation of chromosomes 9 and 22, and the generation of the BCR–ABL fusion oncogene. The development of tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of CML, as TKI therapy leads to inhibition of BCR–ABL activity, suppression of the BCR–ABL -containing clone and restoration of normal hematopoiesis in the vast majority of cases.

Source: Blood Cancer Journal

DOI: 10.1038/bcj.2016.18

Authors: K Krysiak, M J Christopher, Z L Skidmore, R T Demeter, V Magrini, J Kunisaki, M O'Laughlin, E J Duncavage, C A Miller, B A Ozenberger, M Griffith, L D Wartman, O L Griffith

Institutions: Washington University in St. Louis, Alvin J. Siteman Cancer Center

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $5,290

Funders: National Institutes of Health, National Heart, Lung, and Blood Institute, National Human Genome Research Institute, National Cancer Institute

Awards: G2265240306, G3995156439, HISTONE H3 METHYLATION AND EPIGENOMICS IN ACUTE LEUKEMIA, G5310623310, G5422583638, G6276719192, DEFINING THE REGULATORY, NON-CODING, MUTATIONAL LANDSCAPE OF BREAST CANCER, G9000016593, Pre-and Postgraduate Training in Molecular Hematology

OpenAlex ID: W2332771775

FWCI: 2.106

Cites: 15

Cited by: 17

Related to: 10